Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Sinusitis
Special Issues
The Asthma, Rhinitis and Chronic Pulmonary Diseases
share announcement

The Asthma, Rhinitis and Chronic Pulmonary Diseases

A special issue of Sinusitis (ISSN 2673-351X).

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 6179

Special Issue Editor

Dr. Gurupreet S. Sethi

E-Mail Website
Guest Editor
Center for Autoimmunity and Inflammation, La Jolla Institute for Immunology, 9420 Athena Circle La Jolla, CA 92037, USA
Interests: asthma; allergy; Th2 immune response; lung-resident T cells; memory T cells; airway inflammation; airway hyperresponsiveness

Special Issue Information

Dear Colleagues,

The respiratory system continuously supplies oxygen to the bloodstream and charges up our body to perform various functions. Respiratory illness, however, affects the functioning of the lungs and makes breathing difficult. Notably, the incidence of respiratory diseases is increasing at an alarming rate, even in developed countries. Unfortunately, no cure for respiratory diseases is available; however, current therapies hold promise in terms of partially suppressing clinical symptoms.

With the aim of more closely understanding these respiratory diseases, we are pleased to announce a Special Issue of Sinusitis entitled “Asthma, Rhinitis, and Chronic Pulmonary Diseases”. The term chronic pulmonary diseases (CPDs) refers to respiratory complications such as asthma, chronic obstructive pulmonary disease (COPD), acute lung injury, infections (such as influenza and pneumonia), and many other breathing problems. In this Special Issue, we invite preclinical studies discussing inflammatory and structural changes of the airways associated with CPDs. Thus, this journal provides a platform to discuss the molecular and cellular factors responsible for developing CPDs to find new ways to prevent or, if possible, cure these diseases. We welcome both original research and review articles. We also encourage authors to consider their negative findings, if any, for publication. Accepted manuscripts will be available on our open-access platform, which will be easily accessible by our readers.

Dr. Gurupreet S. Sethi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Sinusitis is an international peer-reviewed open access semiannually journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asthma
  • allergy
  • airway inflammation
  • rhinitis
  • airway remodeling
  • airway hyperresponsiveness
  • chronic obstructive pulmonary disease
  • acute lung injury
  • acute respiratory distress syndrome (ARDS)
  • T cell immune response

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

7 pages, 554 KiB  
Review
Home-Based Respiratory Care for COPD Patients
by Ricardo G. Figueiredo, Caio Laudano, Jaqueline Muniz and José de Bessa, Jr.
Sinusitis 2022, 6(2), 49-55; https://doi.org/10.3390/sinusitis6020007 - 12 Sep 2022
Cited by 1 | Viewed by 3197
Abstract
Despite significant advances in pharmacological treatment over the last few decades, COPD remains a heavy burden on the health systems around the world, affecting approximately 210 million people, with elevated morbimortality and socioeconomic impact. Barriers to healthcare access were even more evident during [...] Read more.
Despite significant advances in pharmacological treatment over the last few decades, COPD remains a heavy burden on the health systems around the world, affecting approximately 210 million people, with elevated morbimortality and socioeconomic impact. Barriers to healthcare access were even more evident during the coronavirus disease 19 (COVID-19) pandemic and increased patients’ vulnerability to physical deconditioning, depression, and social isolation. Home-based respiratory care in patients with COPD provides a valuable contribution to effective disease management, with potential advantages for monitoring, treatment adherence, and cost reduction. Technological innovation allows clinical markers of interest, such as respiratory frequency, pulmonary function, and oxygen saturation, to be tracked remotely from the patients’ homes, providing a better understanding of their real needs. Home-based telerehabilitation can also be a viable alternative to hospital-based programs. Here, we highlight the full extent of health benefits of HRC in COPD, particularly for patients with a higher risk of exacerbations, multiple comorbidities, and limited access to health services. Full article
(This article belongs to the Special Issue The Asthma, Rhinitis and Chronic Pulmonary Diseases)
►▼ Show Figures

Figure 1

4 pages, 825 KiB  
Review
The Role of Dual Bronchodilation and the Conscientious Use of Inhaled Corticosteroid in COPD
by Ricardo G. Figueiredo, Lucas F. Araujo and José de Bessa Junior
Sinusitis 2022, 6(2), 32-35; https://doi.org/10.3390/sinusitis6020005 - 05 Aug 2022
Viewed by 2330
Abstract
Chronic obstructive pulmonary disease (COPD) is a global public health burden that stands out as a leading cause of mortality around the world, especially in less developed countries. COPD treatment should be centered on the individual necessities of each patient, integrating pharmacological therapy, [...] Read more.
Chronic obstructive pulmonary disease (COPD) is a global public health burden that stands out as a leading cause of mortality around the world, especially in less developed countries. COPD treatment should be centered on the individual necessities of each patient, integrating pharmacological therapy, immunization, nutritional support, pulmonary rehabilitation and control of comorbidities. Combining a long-acting antimuscarinic (LAMA) with a long-acting beta2-agonist (LABA) bronchodilator has proven to be more effective than monotherapy with LABA or LAMA, in terms of the functional improvement of forced expiratory volume (FEV1), symptoms and life quality and may be helpful in patients with progressive dyspnea. The eosinophil blood count is a simple biomarker that could guide personalized treatment strategies by identifying patients with greater clinical benefits of inhaled corticosteroid (ICS) treatment. However, one critical concern is the increased risk of pneumonia in individuals treated with ICS. Full article
(This article belongs to the Special Issue The Asthma, Rhinitis and Chronic Pulmonary Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop